UBS Group
SUPN icon

UBS Group’s Supernus Pharmaceuticals SUPN Stock Holding History

UBS Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-45,800
Closed -$1.97M – 7978
2017
Q2 		$1.97M Hold
45,800
– – ﹤0.01% 3025
2017
Q1 		$1.43M Buy
+45,800
New +$1.23M ﹤0.01% 3233

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's SUPN Position: Q1 2026 in Review

UBS Group increased its Supernus Pharmaceuticals (SUPN) stake by 386% in Q1 2026, buying an estimated $8.46M and bringing the position to 209,124 shares worth $10.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3240.

UBS Group first reported a position in SUPN in Q4 2014 and has held it in 46 quarters since. The position peaked at $25.8M in Q3 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • UBS Group held 209,124 shares of Supernus Pharmaceuticals worth $10.8M as of Q1 2026.
  • UBS Group bought 166,077 Supernus Pharmaceuticals shares in Q1 2026, an estimated $8.46M.
  • Supernus Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3240 holding.
  • UBS Group first reported a position in Supernus Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Supernus Pharmaceuticals position peaked at $25.8M in Q3 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.